Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2253-2259

  Stimpfl, Margit ^a   Tong, Dan ^a   Fasching, Barbara ^a   Schuster, Eva ^a   Obermair, Andreas ^a   Leodolter, Sepp ^a   Zeillinger, Robert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; MESSENGER RNA; PRIMER DNA; RNA; SIGNAL PEPTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; BREAST TUMOR; CANCER STAGING; CELL CULTURE; CELL DIFFERENTIATION; CHEMISTRY; DISEASE COURSE; GENETICS; IN VITRO STUDY; LYMPH NODE; MALE; METABOLISM; OVARY TUMOR; PATHOLOGY;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; CELL DIFFERENTIATION; DISEASE PROGRESSION; DNA PRIMERS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMAN; IN VITRO; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPH NODES; LYMPHOKINES; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035992377     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Vascular endothelial growth factor (VEGF) and its receptors
2. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo
3. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
4. Angiogenesis in cancer, vascular, rheumatoid and other diseases
5. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
6. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells
7. Vascular endothelial growth factor is a secreted angiogenic mitogen
8. Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family
9. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
10. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
11. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183
12. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
13. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants
14. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
15. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
16. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells
17. Characterization of novel VEGF binding proteins associated with tumor cells that bind VEGF165 but not VEGF121
18. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
19. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF
20. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo
21. Vascular endothelial growth factor (VEGF) mRNA splice variants are differentially expressed in human blastocysts
22. Xenografts of human solid tumors frequently express cellular-associated isoform of vascular endothelial growth factor (VEGF) 189
23. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer
24. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma
25. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors
26. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma
27. Vascular endothelial growth factor expression in early stage ovarian carcinoma
28. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas
29. Prognostic value of vascular endothelial growth factor in breast cancer
30. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation
31. Differential hormonal regulation of vascular endothelial growth factors VEGF. VEGF-B and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells
32. Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines
33. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis